Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hexafluronium is a synthetic neuromuscular blocking agent used in anesthesiology to prolong and potentiate the skeletal muscle relaxing action of succinylcholine (suxamethonium) during surgery. It acts as a non-competitive reversible inhibitor of human plasma cholinesterase (pseudocholinesterase), binding to anionic side receptors near the enzyme's active center and causing conformational changes that prevent acylation at the esteratic site. This inhibition slows the breakdown of acetylcholine, thereby enhancing and prolonging neuromuscular blockade. Hexafluronium also functions as a nicotinic acetylcholine receptor antagonist, blocking synaptic transmission at skeletal neuromuscular junctions[1][2][5][7]. Its primary clinical use has been as an adjunct to depolarizing muscle relaxants like succinylcholine in surgical anesthesia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hexafluronium.